Pozen Patents Upheld in Treximet Patent Litigation

POZEN Inc. POZN today announced that the United States District Court for the Eastern District of Texas has issued a favorable verdict in the litigation between POZEN and several generic pharmaceutical companies which had filed Abbreviated New Drug Applications seeking approval from the U.S. Food and Drug Administration to market generic copies of Treximet® (sumatriptan / naproxen sodium). Treximet is marketed by POZEN's exclusive U.S. licensee, GlaxoSmithKline GSK. The District Court ruled U.S. Patent Nos. 6,060,499 and 6,586,458 to be valid, enforceable and infringed by Par Pharmaceutical, Inc. PRX, Alphapharm Pty Ltd. (Alphapharm), and Dr. Reddy's Laboratories, Inc. RDY. A third patent, U.S. Patent No. 7,332,183 covering the Treximet formulation was held to be valid, enforceable and infringed by Par and DRL. The ‘183 patent was not asserted against Alphapharm.